Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in radioiodine-refractory differentiated thyroid cancer
CTR20150735Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in well-differentiated thyroid cancer (WDTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Nov 2015; status: completed.
02
Drugs
anlotinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20150735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150735.